| Thursday, September 18, 2025 | |
|---|---|
| 18:45 | Welcome Reception |
| Friday, September 19, 2025 | |
|---|---|
| 09:00-09:10 | Welcome Arnon Nagler, Mohamad Mohty, Dror Mevorach |
| 09:10-11:00 | Session 1: Introduction to CAR-T- and T-cell engagers in autoimmunity Chairs: Arnon Nagler, Josef Smolen |
| 09:10-09:55 | Plenary lecture: SLE pathogenesis and CAR T regulatory cell treatment George Tsokos, USA |
| 09:55-10:30 | Rheumatoid arthritis: From inverse pyramid through biologics to CAR T and BiTE. Historical perspective Josef Smolen, Austria |
| 10:30-11:00 | From SLE to myasthenia gravis: What are the current bispecific/tri-specific T-cell engagers and CAR T in development for autoimmunity? Dror Mevorach, Israel |
| 11:00-11:25 | Coffee break |
| 11:25-13:00 | Session 2: Autoimmunity revisited: Chairs: George Tsokos, Dror Mevorach |
| 11:25-12:05 | A human tumor virus that might cause autoimmunity. Christian Münz, Switzerland |
| 12:05-12:45 | CAR T safety in autoimmune diseases Melanie Hagen, Germany |
| 12:45-13:00 | Industrial Symposium |
| 13:00-14:00 | Lunch |
| 14:00 – 15:30 | Session 3: From haemato-oncology to rheumatology Chairs: Dror Mevorach, Michael Aigner |
| 14:00-14:30 | CAR T-cells: From hematology to autoimmunity Arnon Nagler, Israel |
| 14:30-15:00 | Current European guidelines for HSCT and CAR T in autoimmune diseases Raffaella Greco, Italy |
| 15:00-15:30 | CAR T in neurological autoimmunity Aiden Haghikia, Germany |
| 15:30-15:50 | Coffee break |
| 15:50-17:20 | Session 4: Safety of CAR T and bispecific Miscellaneous cell therapies for autoimmunity Chairs: Arnon Nagler, Aiden Haghikia |
| 15:50-16:20 | Is there a cancer risk in treating patients with CAR T? Remy Dulery, USA |
| 16:20-16:50 | CAR T- BCMA in Autoimmune Diseases Shlomo Elias, Israel |
| 16:50-17:20 | Adverse effects of CAR T treatment Zinaida Perić, Croatia |
| Saturday, September 20, 2025 | |
|---|---|
| 09:00-10:30 | Session 5: Near future perspectives I Chairs: Dror Mevorach, Li Tang |
| 09:00-09:45 | Plenary lecture: Systematic identification of targets improving T-cell therapies Laurie Menger, France |
| 09:45-10:10 | Autoreactive B-cell depletion by CAR T-cells for ANCA vasculitis Avery Posey, Jr., USA |
| 10:10-10:35 | CAR-BCMA for amyloidosis Moshe Gatt, Israel |
| 10:35-11:00 | Coffee break |
| 11:00-12:40 | Session 6: Developing treatment for autoimmunity Chairs: Avery Posey, Jr., Laurie Menger |
| 11:00-11:25 | Are cells from patients with autoimmunity suitable for CAR T generation? Limits and perspectives Michael Aigner, Germany |
| 11:25-11:50 | Our experience with academic CAR-T CD19 for autoimmunity Merav Lidar, Israel |
| 11:50-12:30 | Revitalizing exhausted T cells for enhanced cancer immunotherapy: a journey from lab discovery to clinical application Li Tang, Switzerland |
| 12:30-13:40 | Lunch |
| 13:40-14:40 | Session 7: Near future perspectives II Chairs: Ricardo Grieshaber-Bouyer, Remy Dulery |
| 13:40-14:10 | T-cell engagers in autoimmune diseases Ricardo Grieshaber-Bouyer, Germany |
| 14:10-14:40 | Resetting autoimmunity in immune-mediated inflammatory diseases. Gerhard Krönke, Germany |
| 14:40-16:30 | Session 8: Debates Chairs: Arnon Nagler, Dror Mevorach |
| 14:40-14:50 | Introduction |
| 14:50-15:20 | CAR T or BiTE for autoimmunity? Ricardo Grieshaber-Bouyer, Germany and George Tsokos, USA |
| 15:20-15:45 | Discussion |
| 15:45 | Closing remarks Arnon Nagler, Mohamad Mohty, Dror Mevorach |
